From Financialpost · · 1m
Oncolytics Biotech Secures Patent Extensions
Oncolytics Biotech extends cancer immunotherapy patent protection to late 2040s with new intellectual property updates.
In brief
Oncolytics Biotech extends cancer immunotherapy patent protection to late 2040s with new intellectual property updates. Oncolytics Biotech secures method of use patents for pelareorep immunotherapy and composition of matter patents for next generation version, extending patent protection through late 2040s. Originally…
Patent Update
Oncolytics Biotech provides intellectual property strategy update with new method of use patents for pelareorep immunotherapy.
“Oncolytics Biotech Inc. (Nasdaq: ONCY) provides update on intellectual property strategy”
Global Patent Issuance
New method of use patent for pelareorep as cancer immunotherapy issued in several countries with U.S. patent expected soon.
“A new method of use patent covering pelareorep as an immunotherapy for the treatment of cancer has been issued in several countries”
Pending Applications
Three patent applications pending including two method of use patents with one expected to become U.S. Track One application this quarter.
“Oncolytics has three patent application families pending, including multiple method of use patents”
Track One Application
Company expects to convert one pending application into U.S. Track One application for prioritized examination this quarter.
“This quarter, the Company expects to convert one of these pending applications into a U.S. application submitted with a request for Track One prioritized examination”
Next Generation Pelareorep
Company working with academic partner on modified pelareorep for potential enhanced efficacy with up to 20 years of patent protection.
“In parallel, Oncolytics is working with an academic partner on a modified form of pelareorep that the Company refers to as "next generation" pelareorep”
Patent Strategy
Oncolytics extends patent protection through late 2040s with existing manufacturing protection through 2044.
“The Company expects this work to support the addition of a new composition of matter patent to its portfolio, with the potential for up to 20 years of patent protection measured from the applicable filing date”
The big picture
Oncolytics Biotech secures method of use patents for pelareorep immunotherapy and composition of matter patents for next generation version, extending patent protection through late 2040s.
